Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease

Genç, Halil; Doğru, Teoman; Kara, Muammer; Tapan, Serkan; Erçin, Cemal Nuri; Açıkel, Cengizhan; Karslioğlu, Yıldırım; Bağcı, Sait

doi:10.1016/s1665-2681(19)31338-9

Cited by 53 publications

(52 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, inflammation is thought to contribute to the progression to advanced liver disease (22) and individuals with NAFLD have been shown to have elevations in systemic inflammation (14, 25), which was supported in the present report in the sedentary OLETF rats with elevations in leptin, MCP-1, and IL-6. Additionally, it is known that obesity affects the balance in macrophage polarization within white adipose tissue (1) and similar imbalances may promote inflammation and fibrosis through stellate cell activation in the liver (18, 29).…”

Section: Discussionsupporting

confidence: 86%

Treating NAFLD in OLETF Rats with Vigorous-Intensity Interval Exercise Training

Linden

Fletcher

Morris

et al. 2015

Medicine &Amp; Science in Sports &Amp; Exercise

View full text Add to dashboard Cite

Background There is increasing use of high intensity, interval type exercise training in the management of many lifestyle-related diseases. Purpose To test the hypothesis that vigorous-intensity, interval exercise is as effective as traditional, moderate-intensity aerobic exercise training on nonalcoholic fatty liver disease (NAFLD) outcomes in obese, Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods OLETF rats (age 20 wks; n= 8–10/group) were assigned to sedentary (O-SED), moderate-intensity exercise training (O-MOD EX; 20 meters/min, 15% incline, 60 min/d, 5 d/wk treadmill running), or vigorous-intensity interval exercise training (O-VIG EX; 40 meters/min, 15% incline, 6×2.5 min bouts/d, 5 d/wk treadmill running) groups for 12 weeks. Results Both MOD EX and VIG EX effectively lowered hepatic triglycerides (TGs), serum ALTs, perivenular fibrosis, and hepatic collagen 1α1 mRNA expression (vs. O-SED, p<0.05). In addition, both interventions increased hepatic mitochondrial markers (citrate synthase activity and fatty acid oxidation) and suppressed markers of de novo lipogenesis (FAS, ACC, Elovl6, and SCD-1); whereas, only MOD EX increased hepatic mitochondrial β-HAD activity and hepatic TG export marker apoB100 and lowered fatty acid transporter CD36 compared with O-SED. Moreover, while total hepatic macrophage population markers (CD68 and F4/80 mRNA) did not differ among groups, MOD EX and VIG EX lowered M1 macrophage polarization markers (CD11c, IL-1β, and TNFα mRNA) and MOD EX increased M2 macrophage marker, CD206 mRNA, compared with O-SED. Conclusions The accumulation of 15 min/day of VIG EX for 12 weeks had similar effectiveness as 60 min/day of MOD EX in the management of NAFLD in OLETF rats. These findings may have important health outcome implications as we work to design better exercise training programs for NAFLD patients.

show abstract

Section: Discussionsupporting

confidence: 86%

Treating NAFLD in OLETF Rats with Vigorous-Intensity Interval Exercise Training

Linden

Fletcher

Morris

et al. 2015

Medicine &Amp; Science in Sports &Amp; Exercise

View full text Add to dashboard Cite

show abstract

“…Our study found that serum adiponectin levels increased significantly (liraglutide group) or had an increasing trend (sitagliptin group); in these two groups, the improvement of IHL was also observed. It was also found that IL‐6 was higher in patients with NAFLD compared with non‐NAFLD controls . In our study, serum IL‐6 levels decreased significantly (liraglutide group) or had a decreasing trend (sitagliptin group), and positive correlation was found between ΔIL‐6 and ΔMRI‐PDFF.…”

Section: Discussionsupporting

confidence: 68%

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

et al. 2019

View full text Add to dashboard Cite

To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine in this 26‐week trial. The primary endpoint was the change in intrahepatic lipid (IHL) from baseline to week 26 as quantified by magnetic resonance imaging–estimated proton density fat fraction (MRI‐PDFF). Secondary endpoints included changes in abdominal adiposity (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT]), glycated hemoglobin, and body weight from baseline to week 26. We analysed data from intent‐to‐treat population. MRI‐PDFF, VAT, and weight decreased significantly with liraglutide (15.4% ± 5.6% to 12.5% ± 6.4%, P < 0.001; 171.4 ± 27.8 to 150.5 ± 30.8, P = 0.003; 86.6 ± 12.9 kg to 82.9 ± 11.1 kg, P = 0.005, respectively) and sitagliptin (15.5% ± 5.6% to 11.7% ± 5.0%, P = 0.001; 153.4 ± 31.5 to 139.8 ± 27.3, P = 0.027; 88.2 ± 13.6 kg to 86.5 ± 13.2 kg, P = 0.005, respectively). No significant change in MRI‐PDFF, VAT, or body weight was observed with insulin glargine. SAT decreased significantly in the liraglutide group (239.9 ± 69.0 to 211.3 ± 76.1; P = 0.020) but not in the sitagliptin and insulin glargine groups. Changes from baseline in MRI‐PDFF, VAT, and body weight were significantly greater with liraglutide than insulin glargine but did not differ significantly between liraglutide and sitagliptin. Conclusion: Combined with metformin, both liraglutide and sitagliptin, but not insulin glargine, reduced body weight, IHL, and VAT in addition to improving glycemic control in patients with T2DM and NAFLD.

show abstract

“…Leptin is another major adipocytokine documented to modulate food intake, lipid metabolism, insulin resistance, proinflammatory function [39] and fibrogenesis [40]. Visfatin is a novel adipocytokine with immunomodulating, insulin-mimetic and proinflammatory properties [41], and it has been associated with the liver fibrosis in NAFLD patients [42]. Better understanding of the pathogenic role of adipocytokines in hepatic inflammation and fibrogenesis will help prevent liver fibrosis progression, improve antiviral therapy response in patients with chronic liver diseases, and deserve further studies [13,41,43].…”

Section: Discussionmentioning

confidence: 99%